MedTrace Logo

Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)

NCT06167590 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-12-12

No results posted yet for this study

Summary

The aim of this study is to identify biologically viable targets for the treatment of major depressive disorder (MDD) and anxiety disorder (AD) with the ultimate goal of guiding physicians' therapeutic strategies and identifying more effective and safer treatments for patients. Following the inclusion and exclusion criteria, the investigators will recruit 10 patients with a diagnosis of anxious-depressive disorder (MDD-AD) and 10 healthy controls (HC) subjects. Each participant will be evaluated by a team of expert psychologists and physicians, who will be conducting a structured interview and administering a set of psychopathological scales to assess the symptoms' severity. The participants will also undergo7T multimodal neuroimaging session (including T1-weighted, 1H-MRS and fMRI).

In the second part of the study, murine models will be used to study the role of integrin β3 (Itgb3) and protocadherin 9 (Pcdh9) in glutamatergic transmission at a molecular level and to evaluate whether the electrophysiological and behavioral defects identified in Itgb3- and Pcdh9-knockout mice can be restored by CRISPR-mediated transcription activation (CRISPRa).

Conditions

  • Depression, Anxiety
  • Healthy

Interventions

DIAGNOSTIC_TEST

GAPsy protocol

Each participant will undergo a 7 T multimodal neuroimaging session, including T1-weighted, 1H-MRS and fMRI. Each participant will also be assessed through a structured clinical interview (SCID-I e SCID-II) and will be administered scales such as HAM-A, HAM-D, BPRS and MADRS.

Sponsors & Collaborators

  • CNR Institute of Neuroscience, Parma

    collaborator OTHER

  • University of Trieste

    collaborator OTHER

  • IRCCS Fondazione Stella Maris

    collaborator OTHER

  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

    lead OTHER

Principal Investigators

  • Sara Maria Pozzoli, PhD · S. C. Psichiatria - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-15
Primary Completion
2024-07-14
Completion
2025-07-14

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06167590 on ClinicalTrials.gov